Skip to content
DataLookout
Menu

NCT07829107

The PIONEER Comparative Effectiveness Study - Project 2

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 1, 2026 to Oct 15, 2026
    • Site details revised at 6 of 6 sites
  2. Minor Study sites revised (6)
  3. Notable Eligibility criteria expanded, about 1 word
    • Secondary endpoints revised (8)
    • Primary endpoint revised
    • Site contacts updated at 2 of 6 sites
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The proportion of eligible emergency department (ED) patients with suspected traumatic brain injury (TBI) who receive brain CT imaging.
Timeframe: Initial Emergency Department Visit (approximately 24 hours)

Secondary (8)

Proportion of eligible ED patients with suspected TBI who receive brain CT imaging and have a clinically significant traumatic lesion.
Incidence of clinically significant missed traumatic intracranial injury diagnosed within 7 days of the index ED visit
Incidence of neurosurgical interventions within 7 days of the index ED visit, without a new traumatic event.
ED length of stay
Initial and sustained provider adherence at 6 and 24 months post-implementation
Show 3 moreShow less
Provider acceptability and feedback
Provider trust in biomarker-guided CT decision making as measured by the proportion of biomarker-negative patients who don't get a CT
30-day ED revisits and hospitalizations

Arms and interventions

Clinical Pathway 2: Clinical Guidelines OnlyActive comparator

Clinical Guidelines Only (Canadian CT Head Rule)

Clinical Pathway 1: Guidelines + BiomarkersExperimental

Canadian CT Head Rule plus whole blood Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) measurement using the i-STAT.

Diagnostic tests: Clinical pathway 1: Guidelines plus biomarkers, Clinical guidelines only

Sites

6 sites in 1 country